FMP

FMP

Enter

LEXX - Lexaria Bioscience C...

photo-url-https://images.financialmodelingprep.com/symbol/LEXX.png

Lexaria Bioscience Corp.

LEXX

NASDAQ

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

1.19 USD

-0.04 (-3.36%)

LEXX Financial Statements

Quarter

2025 Q2

2025 Q1

2024 Q4

2024 Q3

Total Revenue

174k

183.92k

84k

84k

Cost of Revenue

0

2.72k

0

0

Gross Profit

174k

181.2k

84k

84k

Operating Expenses

2.93M

2.87M

2.29M

1.83M

Research and Development

1.69M

1.95M

967.21k

573.09k

Selling, General & Administrative Expenses

1.24M

918.69k

1.32M

1.25M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

1.24M

918.69k

1.32M

1.25M

Other Expenses

0

0

0

0

Operating Income

-2.75M

-2.69M

-2.2M

-1.74M

Total Other Income/Expenses Net

37.8k

-12.99k

16.49k

-41.39k

Income Before Tax

-2.71M

-2.7M

-2.19M

-1.78M

Income Tax

3.76k

0

0

0

Net Income

-2.71M

-2.7M

-2.18M

-1.78M

Basic EPS

-0.15

-0.16

-0.17

-0.13

EPS Diluted

-0.15

-0.16

-0.17

-0.13

Basic Average Shares

17.51M

16.67M

13.12M

13.86M

Diluted Average Shares

17.51M

16.67M

13.12M

13.86M

EBITDA

-2.75M

-2.69M

-2.2M

-1.73M

Retained Earning Schedule

Quarter

2025 Q2

2025 Q1

2024 Q4

2024 Q3

Retained Earnings (Previous Year)

-54.26M

-51.56M

-49.37M

-47.59M

Net Income

-2.71M

-2.7M

-2.18M

-1.78M

Stock Repurchases

0

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-56.98M

-54.26M

-51.56M

-49.37M

Other Distributions

-2.71M

-2.7M

-2.18M

-1.78M

PPE Schedule

Quarter

2025 Q2

2025 Q1

2024 Q4

2024 Q3

Gross PPE

358.33k

398.65k

389.55k

362.61k

Annual Depreciation

0

0

-7.76k

15.07k

Capital Expenditure

0

0

-69.59k

-22k

Net PPE

358.33k

398.65k

466.9k

369.53k

Intangible and Goodwill Schedule

Quarter

2025 Q2

2025 Q1

2024 Q4

2024 Q3

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep